1800-272-662
Shopping Cart 0
countryflagAU
Login

Immuron Ltd

Healthcare AU IMC

0.031AUD
0.002(6.90%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.030.03
LowHigh

52 Week Range

0.030.10
LowHigh

Fundamentals

  • Previous Close 0.03
  • Market Cap9.80M
  • Volume200567
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.73953M
  • Revenue TTM7.48M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 4.76M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -5.21599M -6.93696M -4.17938M -2.85425M -8.81550M
Minority interest - - - - -
Net income -5.21599M -6.93696M -3.78651M -2.85425M -8.38447M
Selling general administrative 4.48M 4.52M 4.22M 3.52M 6.09M
Selling and marketing expenses 3.45M 2.03M 0.93M 0.42M 0.29M
Gross profit 4.77M 3.34M 1.31M 0.52M 0.09M
Reconciled depreciation 0.05M 0.05M 0.05M 0.04M 0.04M
Ebit -5.35673M -6.23834M -3.84540M -3.10557M -8.37070M
Ebitda -5.30704M -6.19236M -3.79673M -3.07896M -8.32704M
Depreciation and amortization 0.05M 0.05M 0.05M 0.03M 0.04M
Non operating income net other - - - - -
Operating income -5.34455M -5.80112M -6.00040M -4.05914M -8.41448M
Other operating expenses 12.63M 10.70M 5.37M 3.64M 8.56M
Interest expense 0.00730M 0.00758M 0.00965M 0.00618M 0.01M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.14M 0.33M 0.11M 0.02M 0.00920M
Net interest income 0.13M 0.32M 0.11M 0.02M -0.00456M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.76498M -0.39288M -0.25750M -0.43103M
Total revenue 7.29M 4.90M 1.80M 0.77M 0.15M
Total operating expenses 10.11M 9.14M 4.88M 4.58M 8.51M
Cost of revenue 2.52M 1.57M 0.50M 0.24M 0.05M
Total other income expense net 0.13M -1.13584M 1.82M 0.02M -0.00456M
Discontinued operations - - - - -
Net income from continuing ops -5.21599M -6.93696M -3.78651M -2.85425M -8.38447M
Net income applicable to common shares -5.21599M -6.93696M -3.78651M -2.85425M -8.38447M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 10.13M 15.55M 21.99M 24.86M 27.05M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.00767M 0.10M 0.16M 1.03M 0.08M
Total liab 2.06M 2.84M 2.37M 1.68M 1.16M
Total stockholder equity 8.07M 12.71M 19.62M 23.18M 25.90M
Deferred long term liab - - - - -
Other current liab 0.05M 0.56M 0.29M 0.03M 0.02M
Common stock - 88.50M 88.44M 88.44M 88.36M
Capital stock 88.87M - 88.44M 88.44M 88.36M
Retained earnings -82.44321M -78.96840M -72.05540M -68.42528M -65.93289M
Other liab - - 0.00188M 0.00004M 0.04M
Good will - - - - -
Other assets - - 1.22M 0.96M 1.27M
Cash 2.83M 11.66M 17.16M 22.11M 25.05M
Cash and equivalents - - - - -
Total current liabilities 1.97M 2.70M 2.22M 1.50M 1.12M
Current deferred revenue - - 0.70M 0.71M 0.97M
Net debt - -11.65732M -16.97067M -21.93487M -25.02678M
Short term debt - - 0.04M 0.03M 0.02M
Short long term debt - - - - -
Short long term debt total - - 0.19M 0.18M 0.02M
Other stockholder equity - - 0.11M 3.17M 3.47M
Property plant equipment - - 0.20M 0.23M 0.03M
Total current assets 10.02M 14.73M 20.41M 23.67M 25.75M
Long term investments - - 0.16M - -
Net tangible assets - - 19.62M 23.18M 25.90M
Short term investments - - 1.83M 1.83M -
Net receivables 0.79M 1.39M 0.42M 0.66M 0.33M
Long term debt - - - - -
Inventory 1.77M 1.58M 0.84M 0.33M 0.29M
Accounts payable 1.01M 2.14M 1.19M 0.72M 0.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 3.17M 3.24M 3.17M 3.47M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00067M 0.67M 1.22M 0.96M 1.27M
Deferred long term asset charges - - - - -
Non current assets total 0.11M 0.82M 1.58M 1.18M 1.30M
Capital lease obligations 0.07M - 0.19M 0.21M 0.02M
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -2.90041M 0.33M -2.62128M 0.01M 0.00257M
Change to liabilities - - 0.69M 0.29M 0.59M
Total cashflows from investing activities -2.90041M 0.33M -2.73760M 0.01M 0.00257M
Net borrowings -0.06566M -0.01559M -0.03501M -0.03626M -0.04061M
Total cash from financing activities 0.20M 0.00083M -0.03501M -0.03626M 26.49M
Change to operating activities - - 1.26M -0.49414M -0.04507M
Net income -5.21599M -6.93696M -3.78651M -2.85425M -8.38447M
Change in cash -8.82679M -5.50245M -4.95051M -2.93700M 21.80M
Begin period cash flow 11.66M 17.16M 22.11M 25.05M 3.25M
End period cash flow 2.83M 11.66M 17.16M 22.11M 25.05M
Total cash from operating activities -6.13695M -5.88014M -2.48852M -3.13219M -4.08330M
Issuance of capital stock 0.40M 0.02M 0.00000M 0.00000M 29.28M
Depreciation 0.05M 0.05M 0.05M 0.03M 0.04M
Other cashflows from investing activities 0.14M 0.33M -2.61354M 0.02M 0.00920M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory 0.48M -0.19428M -0.77610M 0.28M 0.96M
Change to account receivables -0.55725M -0.95847M 0.23M -0.33700M 0.02M
Sale purchase of stock 0.40M 0.02M 0.00000M 0.00000M 29.28M
Other cashflows from financing activities -0.00730M -0.00758M -0.04467M -0.04245M -2.74687M
Change to netincome - - -0.25625M -0.05023M 2.74M
Capital expenditures 0.00000M 0.00019M 0.00774M 0.01M 0.00663M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.52151M -0.08471M 1.40M -0.26992M 1.53M
Stock based compensation 0.30M 0.00330M 0.23M 0.09M 2.12M
Other non cash items -0.75338M 1.09M 0.47M -0.20563M 1.25M
Free cash flow -6.13695M -5.56015M -2.49626M -3.14224M -4.08993M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMC
Immuron Ltd		 0.002 6.90% 0.03 - - 1.31 0.72 0.90 1.15
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Immuron Ltd

62 Lygon Street, Carlton, VIC, Australia, 3053

Key Executives

Name Title Year Born
Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA Chief Exec. Officer 1968
Dr. Jerry Kanellos Ph.D. Chief Operating Officer 1961
Mr. Phillip Allen Hains BBus(Acc), CA, MBA CFO & Company Sec. 1959
Mr. David Lyon Head of Marketing NA
Dr. Dan Ruben Peres Chief Medical Officer 1976
Mr. Flavio Palumbo Chief Commercial Officer NA
Mr. Steven George Lydeamore CPA, M.B.A. Chief Executive Officer 1968
Mr. Flavio Palumbo Chief Commercial Officer 1974
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary 1959
Mr. Steven George Lydeamore CPA, M.B.A. Chief Executive Officer 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.